CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic illnesses, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The company's CEO, Rachel Leheny, Ph.D., will deliver a presentation on Wednesday, February 12, 2025, at 8:00 a.m. ET. Interested parties can access a live webcast of the presentation through CalciMedica's IR website under the 'Upcoming Events' section. The presentation recording will remain available on the company's website for 90 days following the event.
CalciMedica (Nasdaq: CALC), un'azienda biofarmaceutica in fase clinica specializzata in terapie di inibizione dei canali CRAC per malattie infiammatorie e immunologiche, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale di Oppenheimer sulle Scienze della Vita e della Salute.
Il CEO dell'azienda, Rachel Leheny, Ph.D., offrirà una presentazione mercoledì 12 febbraio 2025, alle 8:00 a.m. ET. Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso il sito web delle relazioni con gli investitori di CalciMedica nella sezione 'Eventi Futuri'. La registrazione della presentazione rimarrà disponibile sul sito web dell'azienda per 90 giorni dopo l'evento.
CalciMedica (Nasdaq: CALC), una empresa biofarmacéutica en etapa clínica especializada en terapias de inhibición de los canales CRAC para enfermedades inflamatorias e inmunológicas, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Vida y la Salud de Oppenheimer.
La CEO de la empresa, Rachel Leheny, Ph.D., presentará el miércoles 12 de febrero de 2025, a las 8:00 a.m. ET. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través del sitio web de relaciones con inversionistas de CalciMedica en la sección 'Eventos Próximos'. La grabación de la presentación estará disponible en el sitio web de la empresa durante 90 días después del evento.
CalciMedica (Nasdaq: CALC)는 염증 및 면역 질환을 위한 CRAC 채널 억제 치료제를 전문으로 하는 임상 단계의 생명 과학 회사로, Oppenheimer 제35회 연례 헬스케어 생명 과학 컨퍼런스에 참가한다고 발표했습니다.
회사의 CEO인 Rachel Leheny, Ph.D.는 2025년 2월 12일 수요일 오전 8시 (ET)에 발표를 진행합니다. 이해관계자들은 CalciMedica의 IR 웹사이트 '향후 이벤트' 섹션을 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 발표 녹화는 행사 종료 후 90일 동안 회사 웹사이트에서 이용 가능합니다.
CalciMedica (Nasdaq: CALC), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies d'inhibition des canaux CRAC pour les maladies inflammatoires et immunologiques, a annoncé sa participation à la 35e Conférence Annuelle Oppenheimer sur la Santé et les Sciences de la Vie.
La PDG de l'entreprise, Rachel Leheny, Ph.D., présentera le mercredi 12 février 2025, à 8 h 00 (ET). Les parties intéressées peuvent accéder à une diffusion en direct de la présentation via le site Web des relations investisseurs de CalciMedica, dans la section 'Événements à venir'. L'enregistrement de la présentation restera disponible sur le site de l'entreprise pendant 90 jours après l'événement.
CalciMedica (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf CRAC-Kanal-Inhibitionstherapien für entzündliche und immunologische Erkrankungen spezialisiert hat, hat seine Teilnahme an der 35. jährlichen Oppenheimer Healthcare Life Sciences-Konferenz bekannt gegeben.
Die CEO des Unternehmens, Rachel Leheny, Ph.D., wird am Mittwoch, den 12. Februar 2025, um 8:00 Uhr ET eine Präsentation halten. Interessierte Parteien können über die IR-Website von CalciMedica im Abschnitt 'Zukünftige Veranstaltungen' auf einen Live-Webcast der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird 90 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
Contact Information
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366737.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch CalciMedica's (CALC) Oppenheimer Conference presentation?
How long will CalciMedica's (CALC) Oppenheimer Conference presentation be available for replay?
What type of therapies is CalciMedica (CALC) developing?
